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Ischemic heart disease is the single leading cause of death and a significant cause of morbidity among 
women in industrialized countries. Current guidelines recommend antiplatelet therapy as the main 
cornerstone for the prevention and treatment of cardiovascular disease. Unfortunately, evidence is 
emerging that the response to antiplatelet drugs differs according to sex, although the biological basis 
for this gender disparity is unknown. In order to explain the epidemiological data showing a more 
severe clinical expression of cardiovascular disease in addition to adverse outcomes despite optimal 
pharmacological and interventional approaches in women compared to men, differences in platelet 
reactivity related to sex and gender are currently under investigation. In this report, we review avail-
able data from clinical trials of antiplatelet drugs administered for primary and secondary prevention, 
focusing on the underenrollment of female subjects in interventional randomized studies and weak 
community awareness of the impact of cardiovascular disease on life expectancy in women. Based on 
our findings, the development of real gender-oriented evidence-based guidelines for antiplatelet use 
in the setting of cardiovascular disease is urgently required.
J Atheroscler Thromb, 2015; 22:109-125.
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Introduction
In USA, the Institute of Medicine has repeatedly 
affirmed that sex and gender strongly influence the 
natural course of diseases from prevention to diagnosis 
and therapy. This phenomenon may depend on evi-
dent biological differences (sex) between men and 
women that lead to obvious differences in pharmaco-
kinetic parameters (absorption, distribution, metabo-
lism and elimination)1, 2). However, gender (consid-
ered to be the result of the sex-related sociocultural 
processes) differences are also considered to be rele-
vant. Heart disease is closely linked with social roles, 
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stress, lifestyle factors and access to health care sys-
tems. Although the terms sex and gender are com-
monly used interchangeably, for the purpose of this 
review the term sex-gender differences (SGD) will be 
used to describe differences between men and women. 
As largely discussed by Marino et al.1, 2), SGD reflect 
physiological distinctions between the sexes as well as 
environment influences dictated by differences in life-
style.
Although cardiovascular disease (CVD) repre-
sents the main cause of morbidity and mortality in 
both sexes worldwide, there are clear disparities 
between men and women in terms of the clinical pre-
sentation, symptoms, response to therapy and out-
comes3, 4). Throughout the last decade, improvements 
in the diagnosis and treatment of atherosclerosis have 
resulted in a marked reduction morbidity and mortal-
ity in men, whereas the rates of recurrent athero-
thrombotic events, including cardiovascular (CV) 
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any public CV health protective intervention.
Women play an important role in achieving pop-
ulation-based improvements in CVD awareness, as 
they play a role in health prevention and access in 
families, select personal and family healthcare provid-
ers and engage the family unit in health interventions, 
as their own health is preserved7). However, for 
decades, clinicians, as well as women, were “unaware” 
of the impact of coronary artery disease on women’s 
health18). Furthermore, the CRUSADE National 
Quality Improvement Initiative documented that 
women with CVD less often receive guideline-recom-
mended antithrombotic therapies than men19).
Only within recent years, has the effects of CVD 
on the health status of American women gained more 
recognition and become a focus of public education 
efforts, such as the “Go Red for Women” campaign, 
sponsored by the American Heart Association, or the 
“Red Dress” project sponsored by the Department of 
Health and Human Services, National Institutes of 
Health and National Heart Lung and Blood Institute. 
These programs are, partially, a response to the 
increasing awareness of CVD as a major source of 
morbidity and mortality in U.S. women20).
In addition, there are continuous efforts by fed-
eral agencies and scientific societies to increase the 
enrollment of female subjects in CV trials in order to 
obtain more evidence-based data regarding CV treat-
ments for women. For example, the FDA’s Center for 
Devices and Radiological Health recently published a 
Guidance Document “on the study and analysis of 
sex/gender difference in CV medical device trials,” 
underlining the need for solid data to ensure the safe 
and effective use of medical therapies and devices in 
both sexes21, 22). Moreover, the European Heart Health 
Strategy (EuroHeart) project endorsed by the Euro-
death, in women have increased5).
In particular, while the number of deaths among 
men has been steadily declining over the past 15-20 
years, the frequency of CV deaths among women 
remained flat or increased slightly during the 1980’s 
and 1990’s. For over 20 years, the number of deaths 
among women has exceeded that observed in men5). 
Notably, a significant decrease in mortality was observed 
after the great effort to increase CVD awareness among 
women in America between 1996 and 20094, 5).
However, although CVD remains the leading 
cause of death for women in western Countries4) and 
more women die from CVD than from all cancers 
combined6), women remain largely unaware of their 
risk of developing CVD (Fig.1). Heart disease is com-
monly considered a “man’s disease,” and, unfortu-
nately, approximately 36% of women did not perceive 
themselves as being at risk for CVD3, 4, 7), thus result-
ing in an inadequate approach to prevention.
Various SGD in the clinical presentation of CVD 
have been demonstrated, and some therapeutic 
options may not be equally effective and safe in men 
and women6-9). Certainly, gender differences in phar-
macokinetics and pharmacodynamics may contribute 
to different responses to CV drugs1, 8-11). In addition, 
different responses have been described with respect to 
reperfusion techniques. Notably, women with acute 
myocardial infarction (MI) have a higher mortality 
rate than men, regardless of the reperfusion technique 
used12-16). In the CADILLAC trial17), women (n?562, 
27% of the entire population) with acute MI under-
going primary angioplasty were found to have higher 
mortality rates than men.
This phenomenon may be related to the gener-
ally smaller body surface area and higher prevalence of 
comorbidities among women, such as diabetes, hyper-
tension and hyperlipidemia, that predict death, major 
adverse cardiac events (MACE) and bleeding compli-
cations at one year.
This review focuses attention on the relevance of 
awareness of CV prevention strategies and mortality 
reduction among women in order to revise the guide-
lines for antiplatelet therapy, a cornerstone in primary 
and secondary CVD prevention, in terms of efficacy 
and safety, with the objective of improving women’s 
health care.
Call for the Action of Women in
CVD Management
“Disease awareness,” defined as a basic level of 
knowledge of the existence of a given disease and/or 
its effects in the community, represents a key step in 
Fig.1. Remaining lifetime risk for any type of CVD at age 40 
in the subjects free from previous CVD6).
Two-thirds of men are considered at risk, compared to half of 
women.
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of atherothrombotic events35-38); however there is little 
information available about whether these polymor-
phisms are influenced by sex. Meanwhile, women het-
erozygous or homozygous for the Gp Ib-alpha5C 
allele have a higher incidence of composite endpoint 
(death, MI or unstable angina) compared with those 
homozygous for the Gp Ib alpha-5T allele39), and hor-
monal replacement therapy is associated with a 46% 
lower adjusted risk of CV in women with the -5C 
allele versus the -5TT genotype39). Consequently, it is 
not surprising that the response to antiplatelet therapy 
may be influenced by SGD40-44).
Platelets play a pivotal role in the pathogenesis of 
atherosclerosis and occurrence of acute thrombotic 
events. The importance of platelets in CVD is indi-
rectly confirmed by the benefits of antiplatelet agents 
(particularly aspirin, clopidogrel and Gp IIb/IIIa inhib-
itors) in the clinical setting. However, previous clinical 
trials have suggested that, compared to men, women 
do not receive equal therapeutic advantages from anti-
platelet medications. The physiological mechanisms 
and clinical implications underlying this sex-gender 
disparity have yet to be clearly established.
Recently, Wang Y.T. et al.41) reviewed the scarce 
available data on differences in antithrombotic drug 
responses.
Although concerns have been raised regarding 
the differential benefits of antiplatelet drugs in 
women, the propensity for an increased rate of bleed-
ing among female patients has also been recognized. A 
better understanding of contributing factors to SGD 
in terms of platelet biology is warranted. Such factors 
include: i) differences in the frequency and expression 
of genetic polymorphisms affecting platelet respon-
siveness to agonists (with or without antiplatelet ther-
apy), which may be obtained through population-
based studies and large controlled clinical trials; ii) the 
levels of inflammatory markers and their influence on 
atherothrombotic risks; iii) the effects of hormones on 
the platelet function and activation.
Antiplatelet Drugs for CVD 
Prevention in Women
In daily clinical practice, antiplatelet agents are 
recommended for CVD prevention according to 
international guidelines. Among all antiplatelet drugs 
currently available, we will primarily discuss, from a 
gender-related perspective, the following: i) acetylsali-
cylic acid (ASA), an irreversible inhibitor of cyclooxy-
genases; ii) ADP receptors P2Y12 antagonists (clopi-
dogrel, prasugrel, ticagrelor); and iii) Gp IIb/IIIa 
receptor blockers (abciximab, eptifibatide, tirofiban).
pean Society of Cardiology (ESC) and European 
Heart Network (EHN), co-funded by the European 
Commission, have addressed the issue of the represen-
tation of women in CV clinical research in Europe23).
Corroborating the need for more evidence from 
the female “universe,” it has been pointed out that the 
enrollment rate of women in CV clinical trials funded 
by the National Heart, Lung and Blood Institute 
through all of 2006 remained unchanged when com-
pared to the estimated rate between 1965 and 1998, 
corresponding to only 38% of patients, despite several 
federal mandates calling for an increase in the enroll-
ment of women in clinical studies24, 25). The percent-
age of women is even lower when initial phase (I and 
II) clinical trials are considered26).
In our opinion, another field in which awareness 
should be increased is pharmacological therapy, con-
sidering that the guidelines for CV therapy are pri-
marily based on data obtained in men and male ani-
mals27) and because women have been reported to 
experience more frequent and severe drug reactions1, 10). 
In summary, we include the famous quote from Eng-
lish writer Oscar Wilde, “The world was made for men 
and not for women”28).
Platelet Function and SGD
Unfortunately, there is a significant gap in basic 
and clinical knowledge regarding specific cellular 
mechanisms related to CVD in women. Conse-
quently, the biological basis of SGD in the setting of 
CVD remains a frontier to explore. As previously 
mentioned, the paucity of information related to SGD 
associated with CVD is partly due to the fact that 
women have been neglected in research studies6, 25) 
and because most basic science inquiries into biologi-
cal factors contributing to CVD are predominately 
conducted in male animals27). Moreover, there is 
ongoing failure of research tools to include SGD in 
the study design and analysis.
This fault in study design methodology imbues a 
perpetual bias in studies in the reporting phase. Con-
sequently, evidence based-guidelines recommended for 
both sexes are based only on data obtained by pre-
dominantly in trials based on male populations. Nev-
ertheless, numerous SGD have been described in 
platelet biology29-33). For example, while it has been 
reported that oral contraceptives promote platelet 
aggregation, and controversial data are available 
regarding the effects of the menstrual cycle on the 
platelet function32-35). Regarding genetic polymor-
phisms in platelet glycoproteins (Gp), it has been 
shown that such polymorphisms are linked to the risk 
112 ?????????????
exogenous hormones on the pharmacokinetics of 
ASA51).
As a counterpart to SGD in ASA pharmacokinet-
ics, the response to ASA in CVD primary prevention 
clinical trials differs between women and men52).
In a meta-analysis by Berger et al., among 51,342 
women, 1,285 episodes of MACE (625 strokes, 469 
MIs and 364 CV deaths) were reported, compared to 
a total of 2,047 MACE among 44,114 men. In 
women, ASA therapy was found to be associated with 
a significant reduction in CV events (12%) and stroke 
(17%), a reflection of a reduced rate (24%) of isch-
emic stroke, although there were no significant effects 
on MI or CV mortality. In contrast, although similar 
protection from CV events was noted, men derived 
most of the benefits from a reduction in the risk of MI 
of 32%52). However, when adjusted for multiple com-
parisons53), the reduction in vascular outcomes did 
not differ between men and women (Fig.2). It has 
been suggested that the sex-gender mix accounts for 
25% of the variation in the reported efficacy of ASA 
in reducing the rates of CV events across placebo-con-
trolled trials45).
Therefore, even in studies not involving sex biases 
in patient enrollment, differential beneficial effects of 
ASA have been reported. In the “Prevention of pro-
In particular, sex specific pharmacokinetic pro-
files have been described for ASA, while clopidogrel 
does not show any relevant pharmacokinetic sex dif-
ferences, although it is metabolized by the hepatic iso-
enzymes CYP2B6 and CYP3A41, 10). A potential sex 
and gender clinical difference in the mechanism of 
action of clopidogrel is suggested by the reduced rate 
of responsiveness to ADP-mediated aggregation in ex 
vivo experiments among women treated with clopido-
grel1, 10).
CVD Primary Prevention Studies
Currently there is no clear evidence regarding the 
beneficial effects of antiplatelet drugs in CVD primary 
prevention studies45-50), as summarized in Table 1. It 
is well known that ASA, the antecedent to antiplatelet 
therapy prescribed worldwide, is characterized by a 
sex-specific pharmacokinetic profile in both animals 
and human beings For example, it is absorbed and 
hydrolyzed more rapidly and exhibits a larger distribu-
tion in females than in males51). Additionally, it has 
been reported that the rate of ASA absorption slows 
during the menstrual mid-cycle, suggesting the impor-
tance of sexual hormones in modulating the ASA 
activity. These data are also confirmed by the effects of 
Table 1. Primary prevention studies of aspirin in women
STUDY YEAR
SUBJECTS
(% WOMEN)
AGE eligible
range
(years)
FOLLOW-UP
Mean
(years)
TARGET
POPULATION
ASPIRIN
RANDOMISED
FACTORIAL
COMPARISON
PLACEBO
CONTROL
CV events No/Tot
ASA
WOMEN
CTRL
WOMEN
ASA
MEN
CTRL
MEN
HOT
[45]
1998 18,790 (47) 50-80 3.8
Men and women
with DBP
100-115 mm Hg
75 mg
daily
Three blood
pressure
regimens
Yes 109/4,437 134/4,446 173/4,962 207/4,945
PPP
[46]
2001 4,495 (58) 45-94 3.7
Men and women
with one or more
risk factors for CHD
100 mg
daily
Vitamin E
open control
No 17/1,277 26/1,306 28/949 38/963
WHS
[47]
2005 39,876 (100) ≥45 10.0
Female health
professionals
100 mg
alternate days
Vitamin E Yes 477/19,934 522/19,942 ? ?
POPADAD
[48]
2008 1,276 (56) ≥40 6.7
Men and women
with diabetes and
ABI ≤0.99
100 mg
daily
Antioxidant Yes 48/352 55/361 68/286 62/267
JPAD
[49]
2008 2,539 (45) 30-85 4.3
Men and women
with diabetes
81 mg or 100
mg daily
Non aspirin-
treatment
Yes 28/556 35/596 40/706 51/681
AAA
[50]
2010 3,350 (72) 50-75 8.2
Men and women
in general population
with ABI ≤0.95
100 mg
daily
No Yes 85/1,194 93/1,202 96/481 83/473
Legend: AAA: Aspirin for Asymptomatic Atherosclerosis trial; ABI: Ankle-Brachial Index; CHD: coronary heart disease; CTRL: controls; CV: cardiovascular; DBP: diastolic blood pressure; HOT: Hypertension 
Optimal Treatment Trial; JPAD: The Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes; n.a: not available; PPP: Primary Prevention Project; POPADAD: The Prevention Of Progression 
of Arterial Disease And Diabetes Trial; WHS: Women’s Health Study.
113???????????????????????????????
low ABI (defined as an ABI equal to or less than 0.95) 
entered the trial. The sample was powered to detect a 
25% proportional risk reduction in events. Conse-
quently, ASA was found to be no more effective than 
the placebo in reducing the primary endpoint (13.7 
events per 1,000 person-years in the ASA group vs. 
13.3 events per 1,000 person-years in the placebo 
group; HR, 1.03; 95% CI, 0.84-1.27), and the authors 
concluded that ASA had no clinical benefits and may 
actually be harmful in asymptomatic PAD patients.
Of note, the 9th ACCP Guidelines for CVD 
prevention state that, in asymptomatic individuals, 
low-dose ASA therapy (75-100 mg/d) should be con-
sidered in patients ?50 years of age, irrespective of 
gender54).
CVD Secondary Prevention Studies
Over the years, strategies for secondary preven-
tion of CV events have become progressively more 
important to counteract the risk of mortality and 
MACE recurrence, such as after MI6) (Fig.3).
Single Therapy
Antiplatelet agents are a therapeutic cornerstone 
in the secondary prevention of CV events in patients 
with established atherosclerosis. The essential role of 
antiplatelet therapy has been well established in serial 
gression of arterial disease and diabetes” (POPADAD) 
study48), 1,276 patients (50% females) with diabetes 
and asymptomatic peripheral artery disease (PAD) (as 
determined according to a lower-than-normal ankle-
brachial pressure index of 0.99 or less, without symp-
toms) over 40 years of age were randomized to receive 
either ASA (100 mg) or placebo, an antioxidant or 
placebo or ASA and an antioxidant or double placebo 
and followed over eight years. The trial documented no 
benefits from daily prophylactic ASA use (HR?0.98; 
p?0.87). However, it is important to recognize that 
the POPADAD is smaller than most other ASA trials, 
with fewer events, and that it is possible that small 
effects may be demonstrated in larger trials continued 
for longer periods.
Starting in 2010, the rate of enrollment of women 
in CVD primary prevention studies increased (more 
than 50%). Not surprisingly (based on previous evi-
dence), trials have shown no significant benefits to 
ASA treatment among women, as in the “Aspirin for 
Asymptomatic Atherosclerosis” (AAA) trial50). The 
AAA trial was an intention-to-treat, double-blind, 
randomized controlled trial of once daily low-dose 
ASA (100 mg) vs a placebo that involved 28,980 sub-
jects (72% of the participants were women) 50 to 75 
years of age who were free of clinical CVD. All 
recruited patients underwent an ankle-brachial index 
(ABI) screening test. Of these subjects, 3,350 with a 
Fig.2. Rates of cardiovascular and bleeding events per year in the primary prevention studies53).
GI?gastrointestinal; MACE?Major Adverse Cardiovascular Events
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tion (NSTEMI) patients, a smaller absolute (1.2% vs. 
2.8%) and relative (12% vs. 25%) risk reduction in 
the composite endpoint of CV death, non-fatal MI or 
stroke after a one-year follow-up was seen in women 
versus men treated with clopidogrel plus ASA com-
pared to ASA alone at one year56, 57).
The “Clopidogrel for the Reduction of Events 
During Observation” (CREDO) trial58, 59), which 
enrolled patients undergoing elective percutaneous 
coronary intervention (PCI), showed a 26.9% relative 
risk reduction in favor of clopidogrel for the compos-
ite endpoint of death, MI and stroke at one year in 
the overall population. Compared to the results of the 
CURE trial, the CREDO trial demonstrated a greater 
risk reduction among women for the combined risk of 
death, MI and stroke at one year (32% vs. 25%). 
Moreover, in the “Clopidogrel as Adjunctive Reperfu-
sion Therapy – Thrombolysis in Myocardial Infarction 
28” (CLARITY-TIMI 28) trial, patients receiving fibri-
nolytic therapy within 12 hours after the onset of ST 
elevation myocardial infarction (STEMI) symptoms 
were randomized to receive dual antiplatelet therapy 
with ASA plus clopidogrel versus clopidogrel alone60). 
Consequently, a 36% reduction in the risk of the 
composite ischemic endpoint was observed in the sub-
jects treated with clopidogrel among the overall popu-
lation, with similar reductions for both men and 
women (35% vs. 38%, respectively), despite a higher 
publications of the Antithrombotic Trialists’ Collabo-
ration (ATC) including over 130,000 patients and 50 
trials55). This meta-analysis clearly demonstrated a car-
dioprotective benefit of antiplatelet therapy in a broad 
population of patients with clinical evidence of ath-
erosclerosis, specifically defined as those with a history 
of MI, acute coronary syndrome, transient ischemic 
attack or stroke as well as coronary or carotid revascu-
larization procedures. Notably, antiplatelet therapy 
resulted in equally beneficial effects in women and 
men55) (Fig.4).
Double Therapy: ASA and ADP Receptors/P2Y12 
Antagonists
Gender and sex have not been considered, until 
recently, crucial determinants of antithrombotic ther-
apy in the setting of secondary CVD prevention, as 
evidenced by the small number of women enrolled in 
studies designed to test the efficacy of dual antiplatelet 
therapy56-69) (Table 2) and the lack of drug-response 
SGD sensitivity analyses.
Interventional studies specifically focused on sex-
related differences in the response to clopidogrel sup-
port the concept that clopidogrel is similarly beneficial 
in men and women, although the degree of benefit 
may vary. In the “Clopidogrel in Unstable Angina to 
Prevent Recurrent Ischemic Events” (CURE) trial, 
which included non-ST elevation myocardial infarc-
Fig.3. Rates of cardiovascular events after myocardial infarction6).
CHD: coronary heart disease; MI: myocardial infarction; YRS: years
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sugrel at 10 mg daily plus low-dose ASA over a single 
course of antiplatelet therapy) is recommended for 
secondary prevention in acute coronary syndrome 
(ACS) patients treated with PCI with stent placement 
for the first year after the procedure54).
In the “Trial to Assess Improvement in Thera-
peutic Outcomes by Optimizing Platelet Inhibition 
With Prasugrel - Thrombolysis in Myocardial Infarc-
tion 38” (TRITON-TIMI 38) trial, prasugrel was 
compared to clopidogrel in addition to ASA in ACS 
patients (74% NSTEMI). The combined endpoint 
(death from CV, non-fatal MI or non-fatal stroke) was 
reduced by prasugrel [9.9% vs. 12.1%], with an HR 
of 0.81 [95% CI (0.73-0.90)]. However, the rate of 
major bleeding was significantly higher in the prasug-
rel-treated patients (2.4% vs. 1.8%, p?0.03)64). Simi-
lar to the CURE trial findings, a less pronounced and 
statistically not significant risk reduction in women 
has been reported. In the “PLATelet Inhibition and 
Patient Outcomes” (PLATO) trial, the reversible ADP 
receptor antagonist ticagrelor was also shown to be 
superior to clopidogrel in ACS patients (38% STEMI), 
with a lower rate of the primary endpoint, a compos-
ite of CV death/MI or stroke (9.8% vs. 11.7%)65). A 
sex-gender related subgroup analysis revealed similar 
and statistically significant benefits in both men and 
women.
rate of events in women in both treatment arms60).
Reductions in the primary ischemic endpoint at 
28 days with no heterogeneity in the SGD effect, 
despite higher event rates in women, were also observed 
in the “ClOpidogrel and Metoprolol in Myocardial 
Infarction Trial” (COMMIT), which compared the 
effects of clopidogrel plus ASA versus ASA alone in 
Chinese patients with suspected MI61). In contrast, the 
“Clopidogrel for High Atherothrombotic Risk and 
Ischemic Stabilization, Management and Avoidance” 
(CHARISMA) trial failed to demonstrate any clinical 
benefits associated with the combination of low-dose 
ASA and clopidogrel in asymptomatic patients with at 
least three atherothrombotic risk factors, with no sta-
tistically significant differences between the sexes62).
In order to clarify these conflicting data regard-
ing the relative efficacy and safety of clopidogrel in 
reducing CVD events in both sexes, a meta-analysis of 
all blinded randomized clinical trials comparing clopi-
dogrel and a placebo was performed63), which showed 
no significant SGD in the treatment effect, reducing 
overall CVD events by 14%. Although a greater num-
ber of women experienced bleeding complications, no 
statistically significant differences in safety were noted 
between the sexes63).
Indeed, dual antiplatelet therapy (ticagrelor at 90 
mg twice daily plus low-dose ASA at 75-100 mg daily, 
clopidogrel at 75 mg daily plus low-dose ASA or pra-
Fig.4. Rates of major adverse cardiovascular events and serious vascular events in the secondary prevention studies53).
ASA?acetylsalicylic acid; MACE?Major Adverse Cardiovascular Events
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response to varying stimuli70).
Platelets derived from women without IHD are 
more reactive than those of men in response to stan-
dard concentrations of agonists, such as adenosine 
diphosphate (ADP) and thrombin receptor agonist 
protein71-73). Activated platelets, by releasing cytokines, 
mediate an inflammatory response that further ampli-
fies the platelet response and endothelial activation 
under conditions of plaque rupture74) Becker D.M. et 
al. in the GeneSTAR (Genetic Study of Aspirin Respon-
siveness) trial studied healthy men and women75), 
demonstrating higher platelet reactivity in women 
than men after adjusting for age, risk factors, race, 
menopausal status and hormone therapy74). After the 
administration of ASA therapy, women’s platelets 
remain significantly more reactive than those of men 
in response to collagen or ADP stimulation which, 
according to the investigators, likely reflects “platelet 
activation pathways indirectly related to cyclooxygen-
Gp IIb/IIIa Inhibitors
The response to another type of antiplatelet medi-
cation, Gp IIb/IIIa inhibitors, has also been shown to 
have a sex-specific response1, 10). More adverse events 
with Gp IIb/IIIa inhibitors have been reported in 
women. Indeed, women experience more bleeding than 
men, independent of the treatment type1, 10, 67). Appro-
priate dosing of antithrombotic agents should improve 
the care of women with ACS without ST elevation 
(Fig.5).
Biological Response to Antiplatelet 
Drugs and Recurrence of MACE
Since platelet reactivity plays a pivotal role in 
thrombus formation and atherosclerosis, differences in 
the reactivity of platelets between women and men 
have been assessed using several methods and in 
Table 2. Dual antiplatelet therapy in women and gender-stratified events analyses
STUDY YEAR DESIGN STUDY POPULATION
ACTIVE GROUP
(dual antiplatelet therapy)
CONTROL GROUP
(other antiplatelet drug 
or placebo)
PATIENTS
ENROLLED
(N)
WOMEN
(%)
MEN
(%)
CURE
[56]
2001 RCT
ACS without ST-segment
elevation
CLOP (300 mg loading dose
followed by 75 mg/d)?ASA
(75-325 mg/d)
ASA (75-325 mg/d)?Placebo 12,562 4,836 (39) 7,726 (61)
CREDO
[58]
2003 RCT
Planned PCI or coronary
angiogram
CLOP (300-mg loading dose 
followed by 75 mg/d through 12 
months)?ASA (81-325 mg/d)
Placebo (loading dose followed by 
CLOP 75 mg/d until day 28 then 
placebo)?ASA (81-325 mg/d)
2,116 606 (29) 1,510 (71)
CHARISMA
[62]
2006 RCT
Clinically evident cardiovascular 
disease or multiple risk factors
ASA (75-162 mg/d)?CLOP 
(75 mg/d)
ASA (75-162 mg/d)?Placebo 15,603 4,644 (30) 10,959 (70)
CURRENT OASIS-7
[68]
2010 RCT ACS and intended early PCI
Double-dose CLOP (150 mg for 
7 days followed by 75mg/d)
High-dose ASA (300-325 mg/d)
CLOP-standard dose (75 mg/d)
ASA-Low dose (75-100 mg/d)
17,263 4,234 (25) 13,029 (75)
PLATO
[65, 66]
2009 RCT
ACS, with or without ST-segment
elevation, with an onset of
symptoms during the previous
24 hours
TIC (180 mg loading dose 
followed by 90 mg twice/d)?
ASA (75-100mg/d)
CLOP (300-mg loading dose 
followed by a dose of 75mg/d)?
ASA (75-100 mg/d)
18,624 5,288 (28) 13,336 (72)
TRITON-TIMI 38
[64]
2007 RCT ACS with scheduled PCI
PRA (60 mg loading dose 
followed by 10 mg/d)?
ASA (75-162 mg/d)
CLOP (300-mg loading dose 
followed by a dose of 75mg/d)?
ASA (75-162 mg/d)
13,608 3,605 (27) 10,003 (73)
GRAVITAS
[69]
2011 RCT
Stable CAD or non-ST-elevation
acute coronary syndromes.
Patients with high on-treatment
reactivity 12 to 24 hours after PCI
with drug-eluting stents
CLOP (600 mg followed 
by 150 mg/d)?ASA 
(75-162 mg/d)
CLOP (loading dose of placebo 
followed by 75 mg/d and placebo 
tablet daily)?ASA (75-162 mg/d)
2,214 773 (35) 1,441 (65)
Legend: ACS: acute coronary syndromes; ASA: aspirin; CAD: coronary artery disease; CHARISMA: Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance; 
CLOP: clopidogrel; CREDO: Clopidogrel for the Reduction of Events During Observation; CURE: Clopidogrel in Unstable Angina to Prevent Recurrent Events; CURRENT OASIS-7: Clopidogrel and Aspirin 
Optimal Dose Usage to Reduce Recurrent Events-Seventh Organization to Assess Strategies in Ischemic Symptoms; GRAVITAS: Gauging Responsiveness with A VerifyNow assay-Impact on Thrombosis And 
Safety; PCI: percutaneous coronary intervention; PLATO: Study of Platelet Inhibition and Patient Outcomes; PRA: prasugrel; TRITON-TIMI 38: Trial to Assess Improvements in Therapeutic Outcomes by 
Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38; TIC: ticagrelor.
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Table 2. Dual antiplatelet therapy in women and gender-stratified events analyses (continued)
STUDY
PATIENTS 
ENROLLED
(N)
FU
(months)
C V
EVENTS
WOMEN CTRL
FU CV EVENTS/
N. women (%)
MEN CTRL
FU CV EVENTS/
N. men (%)
WOMEN TREATED
FU CV EVENTS/
N. women (%)
MEN TREATED
FU CV EVENTS/
N. men (%)
Clinical Outcomes
Subgroups analysis by sex
CURE
[56]
12,562 12
MACE 258/2,416 (11) 461/3,887 (12) 231/2,420 (10) 351/3,839 (9)
OR (Active vs Control) 95% CI
M: 0.75 (0.65-0.87)
W: 0.88 (0.73-1.06)
ALL CAUSE 
MORTALITY
140/2,420 (6) 250/3,887 (6) 145/2,420 (6) 214/3,839 (6)
OR ((Active vs Control) 95% CI
M: 0.86 (0.71-1.04)
W: 1.04 (0.82-1.32)
MI 148/2,416 (6) 271/3,887 (7) 118/2,420 (5) 206/3,839 (5)
OR (Active vs Control) 95% CI
M: 0.76 (0.63-0.91)
W: 0.79 (0.61-1.01)
CREDO
[58]
2,116 12
MACE 33/297 (11) 81/766 (11) 24/309 (8) 58/744 (8)
OR (Active vs Control) 95% CI
M: 0.72 (0.50-1.02)
W: 0.67 (0.39-1.17)
ALL CAUSE 
MORTALITY
9/297 (3) 15/766 (2) 7/309 (2) 11/744 (1)
OR (Active vs Control) 95% CI
M: 0.75 (0.34-1.65)
W: 0.74 (0.27-2.02)
MI 24/297 (8) 66/766 (9) 18/309 (6) 52/744 (7)
OR (Active vs Control) 95% CI
M: 0.80 (0.55-1.16)
W: 0.70 (0.37-1.33)
CHARISMA
[62]
15,603 28-35
MACE 149/2,328 (6) 424/5,473 (8) 150/2,316 (6) 384/5,486 (7)
OR (Active vs Control)95% CI
M: 0.90 (0.78-1.03)
W: 0.93 (0.86-1.01)
ALL CAUSE
MORTALITY
106/2,328 (5) 268/5,473 (5) 104/2,316 (5) 267/5,486 (5)
OR (Active vs Control)95% CI
M: 0.99 (0.84-1.18)
W: 0.99 (0.75-1.30)
MI 45/2,328 (2) 155/5,473 (3) 42/2,316 (2) 144/5,486 (3)
OR (Active vs Control) 95% CI
M: 0.92 (0.73-1.16)
W: 0.94 (0.61-1.43)
CURRENT OASIS-7
[68]
17,263 1
Composite CV 
death , MI, 
Stroke
CLOP SD: 126/2,183
(5.8)
ASA SD 110/2,085
(5.3)
CLOP SD: 266/6,520
(4.1)
ASA SD 256/6,554
(3.9)
CLOP HD: 93/2,051 
(4.5)
ASA HD:109/2,149 
(5.1)
CLOP HD: 237/6,509 
(3.6)
ASA HD 247/6,475
(3.8)
HR double vs standard dose 
(95% CI)
CLOP:
M: 0.90 (0.76-1.02)
W: 0.77 (0.59-1.02)
ASA:
M: 0.98 (0.83-1.17)
W: 0.95 (0.73-1.324)
PLATO
[65, 66]
18,624 12
Composite CV 
death , MI, 
Stroke
327/2,633 (13.2) 685/6,658 (11.1) 276/2,655 (11.2) 583/6,678 (9.4)
HR M vs W (95% CI)
HR 1.02 (0.91-1.16)
HR TIC vs CLOP (95% CI)
M 0.86 (0.76-0.97); 
W 0.88 (0.74-1.06)
TRITON-TIMI 38
[64]
13,608 6-15
Composite CV 
death , MI, 
Stroke
229/1,820 (12.6) 592/4,975 (11.9) 187/1,703 (11) 485/5,110 (9.5)
RR (Active vs Control)
M: RR?0.79
W: RR?0.88
GRAVITAS
[69]
2,214 6 na na na na na na
Legend: ASA: aspirin; CLOP: clopidogrel; CREDO: Clopidogrel for the Reduction of Events During Observation; CURE: Clopidogrel in Unstable Angina to Prevent Recurrent Events; CURRENT OASIS-7: 
Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events-Seventh Organization to Assess Strategies in Ischemic Symptoms; CV: cardiovascular; GRAVITAS: Gauging Responsiveness with A 
VerifyNow assay-Impact on Thrombosis And Safety; HD: high dose; HR hazard ratio MACE: Major Adverse Cardiovascular Events; MI: myocardial infarction; PLATO: Study of Platelet Inhibition and Patient 
Outcomes; PRA: prasugrel; RR: risk reduction; SD: standard dose; TIC: ticagrelor; TRITON-TIMI 38: Trial to Assess Improvements in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-
Thrombolysis in Myocardial Infarction 38.
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or clopidogrel in 771 stable CV patients, specific and 
aggregation-based assays were performed twice on two 
separate occasions in order to assess antiplatelet resis-
tance80). The authors observed that neither the specific 
nor aggregation-based assays of antiplatelet drug 
responsiveness added any significant predictive values 
relative to the conventional risk factors for ischemic 
events recurrence in the stable CV patients, and con-
sequently do not support the use of platelet function 
testing for MACE risk evaluation in this setting. Cur-
rently, data regarding SGD in antiplatelet drug respon-
siveness, as evaluated based on any type of platelet 
function tests, are lacking.
Bleeding in Women Undergoing PCI
Historically, women have been reported to have 
higher rates of bleeding following PCI than men, 
although the reasons for the large difference are still 
largely unknown.
SGD have been reported in PCI-secondary bleed-
ing events, the most frequent non-ischemic complica-
tion in ACS patients. Data from real-life management 
in the GRACE registry showed major bleeding rates 
ranging from 2.7% to 4.7%. In a multivariate analy-
sis, the adjusted OR for bleeding was 1.71 (95% CI, 
1.35-2.17) in women compared to men81), indicating 
ase-1”75).
Biological antiplatelet drug responsiveness is highly 
variable and has been linked to CV outcomes in 
patients treated with ASA and/or clopidogrel69, 76, 77). 
As summarized in Table 3, reported data are conflict-
ing, likely due to the use of different clinical settings 
(acute versus stable patients) and differences in the 
timing of platelet function assessments (single vs. 
repeated) and the definition of high on-treatment plate-
let reactivity (HPR). HPR is reported to be predictive 
of ischemic events, with relative risks ranging from 2 
to 4 in meta-analyses of studies primarily involving 
patients with acute vessel injury following ACS or PCI 
and in the early phase of antiplatelet treatment78, 79).
Tests used to evaluate antiplatelet drug respon-
siveness differ according to their specificity for the tar-
gets of ASA and clopidogrel. Aggregation-based assays, 
such as the PFA-100® and agonist-induced platelet 
aggregation tests, provide assessments of global plate-
let reactivity.
Prior studies have examined the relationship 
between platelet reactivity and clinical outcomes using 
single assessments of the platelet function; however, 
on-treatment reactivity varies over time. Recently, in 
the Antiplatelet Drug Resistance and Ischemic Events 
(ADRIE) trial, a prospective study focusing on the 
clinical relevance of the platelet response to ASA and/
Fig.5. Rates of major bleeding in men and women following PCI with or without the administration of GP ?b/?a 
inhibitors [adapted from 86].
GPI?GP ?b/?a inhibitors
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cific clinical contexts, such as atrial fibrillation (AF) 
patients who require stent implantation for ischemic 
heart disease. In such cases, current international rec-
ommendations advocate the use of triple therapy with 
warfarin (INR 2.0-2.5) and aspirin plus clopidogrel in 
AF patients with moderate-to-high thromboembolic 
risks for the shortest possible treatment period (depend-
ing on the stent type and individual’s bleeding)82). 
Meanwhile, the Congestive heart failure, Hyperten-
sion, Age ≥75 years, Diabetes mellitus, Stroke, Vascu-
lar disease, Age 65-74 years, Sex category (CHA2DS2-
VASc) score is, at present, a validated tool for stratify-
that a female sex represent an independent predictor 
of such complications. These findings confirm the 
data obtained in previous studies, demonstrating that 
invasively treated (PCI and/or fibrinolysis reperfusion 
strategies) female patients experience periprocedural 
vascular and bleeding complications more frequently 
than male patients, independent of age. Hence, a 
female sex has been identified to be an independent 
predictor of bleeding in several ACS trials using differ-
ent anticoagulation strategies1, 10, 81).
The risk of bleeding in women under treatment 
with antiplatelet agents is even more important in spe-
STUDY
FOLLOW UP 
(Months)
PLATELET TEST 
EVALUATION
DEFINITION OF
HIGH ON-TREATMENT 
REACTIVITY
CONCLUSIONS
POPULAR
[70]
12
-ADP-induced LTA
(20 ?mol/L)
-AA-induced LTA
(AA 0.5 mg/mL)
-VerifyNow P2Y12-Assay
-VerifyNow Aspirin assay
n.a
Incidence of clinical endpoints was similar between 
women and men despite in women the magnitude 
of on-clopidogrel platelet reactivity as well as 
on-aspirin platelet reactivity using LTA, was 
significantly higher
RECLOSE 2-ACS
[71]
24 -ADP induced-LTA (10 ?M) platelet aggregation ≥70%
HRPR status was significantly associated with 
increased risk of ischemic events at short- and long-
term follow-up.
ADRIE
[74]
36
-TXB2
- VASP-Platelet reactivity index (PRI)
- Aggregation based assays:
AA 1 mM
ADP 5 ?M,
ADP 20 ?M,
Collagen 1 ?M
PFA-100®
-TXB2 ≥12 ng/mL
-VASP-PRI ≥50%
-Aggregation based assays
AA ≥20%
ADP 5 ?M ≥55%
ADP 20 ?M ≥42%
Collagen 1 ?M ≥90th percentile
PFA-100® ≥190
Biological antiplatelet drug responsiveness, 
measured with specific or aggregation-based assays, 
has no incremental predictive value over common 
CV risk factors for MACE recurrence in stable CV 
outpatients
Legend: AA: arachidonic acid; ACS: acute coronary syndrome; ADP: adenosine diphosphate; ADRIE: Antiplatelet Drug Resistance and Ischemic Events; ICD: ischemic cerebrovascular disease; ASA: aspirin; 
CAD: coronary artery disease; CLOP: clopidogrel; LTA: Light Transmission Aggregometry; MACE: Major Adverse Cardiovascular Events; n.a.?not available; PAD?peripheral artery disease; PFA-100: Platelet 
Function Analyzer-100; POPULAR: Do Platelet Function Assays Predict Clinical Outcomes in Clopidogrel Pretreated Patients Undergoing Elective PCI study; RECLOSE 2-ACS: Responsiveness to Clopidogrel 
and Stent Thrombosis 2-ACS study; TXB2: thromboxane B2.
Table 3. Prospective studies: Data on platelet reactivity
STUDY YEAR
STUDY
POPULATION
ANTIPLATELET DUAL 
THERAPY
PATIENTS 
ENROLLED
(N)
WOMEN
(%)
MEN
(%)
POPULAR
[70]
2010
Established CAD
scheduled for elective
stent implantation
ASA (80-100 mg/d)?CLOP 
(dose loading followed by 
75 mg/d)
951
234
(26,4%)
717
(73,6%)
RECLOSE 2-ACS
[71]
2011
ACS undergoing an 
invasive procedure and 
receiving long-term 
antithrombotic treatment
ASA (325 mg/d)?CLOP 
(600 mg loading dose 
followed by 75 mg/d)
1,789
366
(20%)
1,423
(80%)
ADRIE
[74]
2012
Consecutive patients 
with symptomatic 
documented ischemic 
atherothrombotic disease
(CAD, ICD, PAD)
ASA and/or CLOP 771
146
(19%)
625
(81%)
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given that women experience more CV events. Since 
women tend to outlive men, this sex disparity will 
likely worsen in the years to come as the population 
continues to age. Bridging this disparity will require a 
better understanding of sex-gender-specific issues in 
the setting of CVD, including the differential response 
to various proven pharmacological interventions in 
women. Antiplatelet therapy is currently a cornerstone 
among CVD prevention strategies as well as the early 
management of ACS; however, there remains a major 
gap in evidence regarding the actual effects of gender 
on the efficacy of antiplatelet drugs in patients with or 
at risk of CVD.
It is important to clarify possible differences 
between men and women in large prospective cohort 
studies with equal numbers of male and female 
patients. Although it is desirable to develop expert 
consensus guidelines comprising sex-specific recom-
mendations for CVD management, the recently pub-
lished statement from the Italian Society of Cardiol-
ogy (SIC) regarding the platelet function and anti-
platelet therapy in women strongly underlined the 
lack of high-level evidence to support more precise 
and strong recommendations96). Therefore, more stud-
ies focusing on CVD as the primary endpoint with 
adequate representation of women and sufficient 
power to examine SGD are urgently needed. Ulti-
mately, clinicians must be vigilant in ensuring that all 
women receive antiplatelet medications as part of sec-
ondary CVD prevention regimens. However, the 
selection of optimal antiplatelet agents in women 
requires further research.
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